Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-1022 and SCB-1033 Vaccine Study in Healthy Older Adults
NCT06984094Phase 2Active, not recruiting
- Sponsor
- Clover Biopharmaceuticals
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SCB-1022, SCB-1033 in respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV), parainfluenza virus infection, sponsored by Clover Biopharmaceuticals. Started Jun 2025; status: active, not recruiting.
02
Drugs
SCB-1022SCB-1033
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)parainfluenza virus infection
Beyond the preview
Go deeper on NCT06984094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984094.